Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing approval from the Therapeutic Goods Administration (TGA) in Australia for its in-house developed orthopedic surgery robot, SkyWalker. This marks another significant milestone for the company as it expands the global footprint of its innovative medical technology.
SkyWalker’s Advanced Features and Surgical Impact
SkyWalker is designed with a suite of advanced features that include precise operation, efficient collaboration, security protection, and strong compatibility.Before the operation, its planning system can assist doctors in developing a personalized implant plan based on the patient’s preoperative CT scan data and implant model data; during the operation, through registration technology combined with the independently developed high-precision, lightweight robotic arm, precise positioning based on surgical planning can be achieved, osteotomy surgery can be completed quickly, and the accuracy and efficiency of the operation can be improved.
Global Recognition and Market Expansion
Prior to this approval, SkyWalker had already received market clearances in key regions including China, the United States, and the European Union, as well as Brazil. The latest approval from the TGA in Australia further solidifies SkyWalker’s position as a leading orthopedic surgery robot in the global market, highlighting its potential to improve surgical outcomes and patient care on an international scale.-Fineline Info & Tech
